Plain-English translation of NCT07069335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether two different formulations of olaparib work the same way in your body. Olaparib is a medication already used to treat advanced ovarian cancer in people with BRCA gene mutations. The study wants to make sure that a new version of this medication performs just as well as the one you may already be taking.
Pharmaceutical companies sometimes develop new formulations of existing medications to improve manufacturing, reduce side effects, or make treatment more convenient for patients. Before a new version can be used widely, researchers need to confirm that it works identically to the original in your body.
You likely qualify if…
You likely don't qualify if…
You will take one version of the medication for one week, then switch to the other version for the second week with no break in between. The study is divided into two stages—Stage 1 will enroll patients already on this treatment, and if those results look good, Stage 2 will enroll additional participants. Throughout the trial, researchers will take blood samples and monitor you to compare how your body handles each formulation and to watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea